RT Journal Article
SR Electronic
T1 Prognostic significance of protein-coding and long non-coding RNA expression profile in T-cell acute lymphoblastic leukemia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.06.21255823
DO 10.1101/2021.05.06.21255823
A1 Verma, Deepak
A1 Kapoor, Shruti
A1 Sharma, Disha
A1 Singh, Jay
A1 Sharma, Gunjan
A1 Kumari, Sarita
A1 Arora, Mohit
A1 Bakhshi, Sameer
A1 Seth, Rachna
A1 Nayak, Baibaswata
A1 Sharma, Atul
A1 Pramanik, Raja
A1 Palanichamy, Jayanth Kumar
A1 Sivasubbu, Sridhar
A1 Scaria, Vinod
A1 Kumar, Rajive
A1 Chopra, Anita
YR 2021
UL http://medrxiv.org/content/early/2021/05/07/2021.05.06.21255823.abstract
AB T-acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy associated with poor outcome. To unravel gene-expression profile of immunophenotypic subtypes of T-ALL, we did transcriptome analysis in 35 cases. We also analyzed the prognostic relevance of 23 targets: protein-coding genes, histone modifiers and long non-coding RNA (lncRNA) expression profile, identified on RNA sequencing, on an independent cohort of 99 T-ALL cases. We found high expression of MEF2C to be associated with prednisolone resistance (p=0.048) and CD34 expression (p=0.012). BAALC expression was associated with expression of CD34 (p=0.032) and myeloid markers (p=0.021). XIST and KDM6a expression levels were higher in females (p=0.047 and 0.011, respectively). Post-induction minimal residual disease (MRD) positivity was associated with high lncRNA PCAT18 (p=0.04), HHEX (p=0.027) and MEF2C (p=0.007). Early thymic precursor (ETP-ALL) immunophenotype was associated with high expression of MEF2C (p=0.003), BAALC (p=0.003), LYL1 (p=0.01), LYN (p=0.01), XIST (p=0.02) and low levels of ST20 (p=0.007) and EML4 (p=0.03). On survival analysis, MEF2C high expression emerged as significant predictor of 3-year event free survival (EFS) (low 71.78±6.58% vs high 36.57±10.74%, HR 3.5, p=0.0003) and overall survival (OS) (low 94.77±2.96% vs high 78.75±8.45%, HR 4.88, p=0.016) in our patients. LncRNA MALAT1 low expression also emerged as predictor inferior OS (low 76.02±10.48 vs high 94.11±3.31, HR 0.22, p=0.027).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded by DBT-WELLCOME TRUST.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:I confirm all relevant ethical guidelines have been followed, and necessary ethical approval approvals (IESC/T-395/28-11-2014) have been obtained from Institute Ethics Committee For Post Graduate Research, All India Institute of Medical Sciences New Delhi.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available on kind request after publication.